Partner Content Partner Content Poor Glycaemic Control and Tooth Loss Study Poor Glycaemic Control and Tooth Loss Study
Partner Content Partner Content First results of the DiabetRisk study First results of the DiabetRisk study
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
